SYNEXUS CLINICAL RESEARCH MIDCO NO 1 LIMITED
Get an alert when SYNEXUS CLINICAL RESEARCH MIDCO NO 1 LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-01-28 (in 8mo)
Last made up 2026-01-14
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£11M
-62.5% lowest in 5 filed years
Employees
—
Average over period
Profit before tax
-£19M
-3,614.5% lowest in 5 filed years
Net assets
7-year trend · vs Industrials median
Accounts
7-year trend · latest reflected 2024-12-31
| Metric | Trend | 2020-01-01 | 2020-12-31 | 2021-01-01 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Turnover | — | — | — | — | — | — | — | |
| Operating profit | — | — | — | -£150,000 | £467,000 | £190,000 | -£14,000 | |
| Profit before tax | — | -£5,447,000 | — | £8,348,000 | £539,000 | £539,000 | -£18,943,000 | |
| Net profit | — | -£5,836,000 | — | £8,348,000 | £539,000 | £539,000 | -£19,013,000 | |
| Cash | — | — | — | — | — | — | — | |
| Total assets less current liabilities | — | £20,994,000 | — | £29,342,000 | £29,881,000 | — | — | |
| Net assets | — | £20,994,000 | — | £29,342,000 | £29,881,000 | £30,420,000 | £11,407,000 | |
| Equity | £26,830,000 | £20,994,000 | £20,994,000 | £29,342,000 | £29,881,000 | £30,420,000 | £11,407,000 | |
| Average employees | — | 0 | — | 0 | 0 | — | — | |
| Wages | — | — | — | — | — | — | — | |
| Directors' remuneration | — | — | — | — | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
—
Not reported
-
Net assets
-62.5%
£30,420,000 £11,407,000
lowest in 5 filed years
-
Employees
—
Not reported
-
Operating profit
-107.4%
£190,000 -£14,000
-
Profit before tax
-3,614.5%
£539,000 -£18,943,000
lowest in 5 filed years
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2020-01-01 | 2020-12-31 | 2021-01-01 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Return on capital employed | — | — | — | -0.5% | 1.6% | — | — | |
| Gearing (liabilities / total assets) | — | — | — | — | — | 0.0% | 0.6% | |
| Current ratio | — | — | — | — | — | — | 163.96x | |
| Interest cover | — | — | — | -11.54x | 1.17x | 5.28x | — |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- SYNEXUS CLINICAL RESEARCH MIDCO NO 1 LIMITED 2015-06-16 → present
- BROOMCO (4278) LIMITED 2015-01-14 → 2015-06-16
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Forvis Mazars LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors are of the opinion that the Company will have sufficient funds available to finance its operations for a period of at least 12 months following the date of approval of these financial statements and accordingly they have prepared the financial statements on the going concern basis.”
Group structure
- SYNEXUS CLINICAL RESEARCH MIDCO NO 1 LIMITED · parent
- Synexus Clinical Research Acquisitions Limited 1%
- Synexus Clinical Research Limited 1%
- Synexus Limited 1%
- Synexus Polska sp z.o.o 1%
- Synexus Clinical Research SA (Pty) Ltd 1%
- Synexus Magyarorszag Ktf 1%
- Synexus Clinical Research GmbH 1%
- Synexus Ukraine Limited liability 1%
- Synexus Bulgaria 1%
- Synexus Czech sro 1%
- Medical Ctr Synexus Sofia 1%
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 10 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| OAKWOOD CORPORATE SECRETARY LIMITED | Corporate Secretary | 2022-11-29 | — | — |
| AHMED, Syed Waqas | Director | 2023-03-29 | Nov 1979 | British |
| CAMERON, Euan Daney Ross | Director | 2023-03-29 | Mar 1976 | British |
| GREEN, Georgina Adams | Director | 2024-04-18 | Mar 1970 | British |
| SMITH, Anthony Hugh | Director | 2023-03-29 | May 1962 | American |
| STARR, Alison Jane | Director | 2024-04-18 | Jan 1977 | British |
Show 10 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| GREGG, Rhona | Secretary | 2022-11-29 | 2026-03-31 |
| BERTHOUX, Christophe | Director | 2015-01-14 | 2016-05-31 |
| CHAMBERS, Paul Michael | Director | 2016-01-01 | 2016-05-31 |
| EVANS, Hywel | Director | 2015-02-18 | 2016-05-31 |
| HARRIS, Richard Stuart | Director | 2021-06-30 | 2023-03-29 |
| HARTMAN, Brainard Judd | Director | 2016-05-31 | 2020-03-19 |
| JAMES, Julia Mary | Director | 2016-05-31 | 2023-05-24 |
| NEILD, Christopher David | Director | 2016-05-31 | 2020-03-19 |
| NORMAN, David John | Director | 2023-03-29 | 2024-04-18 |
| TONDER, Riaan Van | Director | 2020-03-13 | 2021-06-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Ppd International Investments Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-11-17 | Active |
| Synexus Clinical Research Topco Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2016-11-17 |
Filing timeline
Last 20 of 69 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-12-20 RESOLUTIONS Resolution
- 2025-12-20 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-01 | TM02 | officers | Termination secretary company with name termination date | |
| 2026-01-16 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-12-20 | RESOLUTIONS | resolution | Resolution | |
| 2025-12-20 | RESOLUTIONS | resolution | Resolution | |
| 2025-12-19 | SH01 | capital | Capital allotment shares | |
| 2025-07-28 | AA | accounts | Accounts with accounts type full | |
| 2025-01-14 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-11-11 | AA | accounts | Accounts with accounts type full | |
| 2024-04-23 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-19 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-19 | TM01 | officers | Termination director company with name termination date | |
| 2024-01-15 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-12-19 | AA | accounts | Accounts with accounts type full | |
| 2023-05-25 | TM01 | officers | Termination director company with name termination date | |
| 2023-04-06 | AP01 | officers | Appoint person director company with name date | |
| 2023-04-06 | TM01 | officers | Termination director company with name termination date | |
| 2023-04-06 | AP01 | officers | Appoint person director company with name date | |
| 2023-04-06 | AP01 | officers | Appoint person director company with name date | |
| 2023-04-06 | AP01 | officers | Appoint person director company with name date | |
| 2023-01-18 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 6
- Capital events
- 1
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.